Cargando…
Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells
BACKGROUND: ZAP-70 is an independent negative prognostic marker in chronic lymphocytic leukemia (CLL). Usually, its expression is investigated by flow cytometric protocols in which the percentage of ZAP-70 positive CLL cells is determined in respect to isotypic control (ISO-method) or residual ZAP-7...
Autores principales: | Rossi, Francesca M, Del Principe, Maria Ilaria, Rossi, Davide, Irno Consalvo, Maria, Luciano, Fabrizio, Zucchetto, Antonella, Bulian, Pietro, Bomben, Riccardo, Dal Bo, Michele, Fangazio, Marco, Benedetti, Dania, Degan, Massimo, Gaidano, Gianluca, Del Poeta, Giovanni, Gattei, Valter |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2846891/ https://www.ncbi.nlm.nih.gov/pubmed/20211015 http://dx.doi.org/10.1186/1479-5876-8-23 |
Ejemplares similares
-
Surface-antigen expression profiling of B cell chronic lymphocytic leukemia: from the signature of specific disease subsets to the identification of markers with prognostic relevance
por: Zucchetto, Antonella, et al.
Publicado: (2006) -
Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application
por: Pozzo, Federico, et al.
Publicado: (2013) -
Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance
por: Dal-Bo, Michele, et al.
Publicado: (2009) -
The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells
por: Dal Bo, Michele, et al.
Publicado: (2015) -
TP53 Mutations and Clinical Outcome in Chronic Lymphocytic Leukemia: Is a Threshold Still Needed?
por: Bomben, Riccardo, et al.
Publicado: (2023)